Regentis Biomaterials Ltd
Research Regentis Biomaterials Ltd (RGNT) on Bullrun: market cap USD 8.29M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerRGNT
- ExchangeNYSE MKT
- CountryIsrael
- SectorHealthcare
- IndustryMedical Instruments & Supplies
- CurrencyUSD
- Market capUSD 8.29M
- Financial periodFY2025
- RevenueUSD 0
- Net income-USD 13.65M
- Free cash flow-USD 1.38M
Valuation Snapshot
latest market cap is USD 8.29M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 13.65M | -USD 1.38M | n/a | -24.16 | USD 7.38M | USD 1.20M | USD 4.74M |
| FY2024 | USD 0 | USD 4.80M | -USD 641.00K | n/a | 1.72 | USD 229.00K | USD 573.00K | -USD 41.10M |
| FY2023 | USD 0 | -USD 4.13M | -USD 1.22M | n/a | -24.09 | USD 345.00K | USD 210.00K | -USD 45.91M |
| FY2022 | USD 0 | -USD 1.45M | -USD 1.50M | n/a | -0.29 | USD 1.24M | USD 6.47M | -USD 42.06M |
| FY2021 | USD 0 | -USD 5.14M | USD 130.00K | n/a | -1.05 | USD 2.74M | USD 6.08M | -USD 40.48M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 8.29M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 34.91M | n/a | n/a | n/a |
About Regentis Biomaterials Ltd
Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Regentis Biomaterials Ltd's market cap?
Regentis Biomaterials Ltd's market capitalization is USD 8.29M.
What does Regentis Biomaterials Ltd do?
Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee. The company was incorporated in 2004 and is based in Herzliya, Israel.